Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
B. Sangro, Stephen L. Chan, Robin Kate Kelley, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 448-457
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 175
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102622-102622
Open Access | Times Cited: 47
Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape
Emily N. Kinsey, Hannah M. Lee
Cancers (2024) Vol. 16, Iss. 3, pp. 666-666
Open Access | Times Cited: 38
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults
Abid Suddle, Helen L. Reeves, Richard Hubner, et al.
Gut (2024) Vol. 73, Iss. 8, pp. 1235-1268
Open Access | Times Cited: 18
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
Da Xu, Hongwei Wang, Qun Ma, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Αreti Strati, Christos Adamopoulos, Ioannis Kotsantis, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1235-1235
Open Access | Times Cited: 2
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, S.L. Chan, Laura A. Dawson, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 2
Immunotherapy for hepatocellular carcinoma
Alexa Childs, Gloryanne Aidoo-Micah, Mala K. Maini, et al.
JHEP Reports (2024) Vol. 6, Iss. 10, pp. 101130-101130
Closed Access | Times Cited: 12
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
George Lau, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, et al.
Journal of Hepatology (2024) Vol. 82, Iss. 2, pp. 258-267
Open Access | Times Cited: 10
Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma
Zehao Zheng, Renguo Guan, Rongce Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Advancements in immunotherapy for hepatocellular carcinoma
S. Ascari, Rusi Chen, Caterina Vivaldi, et al.
Expert Review of Anticancer Therapy (2025) Vol. 25, Iss. 2, pp. 151-165
Closed Access | Times Cited: 1
Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies
Deepak Sherpally, Ashish Manne
Cancers (2025) Vol. 17, Iss. 4, pp. 589-589
Open Access | Times Cited: 1
Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets
Yutong Li, Mawieh Hamad, Eyad Elkord
Hepatology International (2025)
Closed Access | Times Cited: 1
CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS
Jianxin Wang, Qi Chen, Qi Shan, et al.
Cancer Letters (2025), pp. 217616-217616
Closed Access | Times Cited: 1
The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions
Huimin Yuan, Ruochen Xu, Senlin Li, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access | Times Cited: 1
Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome
Ye Lin, Wenbo Yue, Hao Shi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Lorenza Rimassa, Stephen L. Chan, Bruno Sangro, et al.
Journal of Hepatology (2025)
Closed Access | Times Cited: 1
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice
Shigeo Shimose, Issei Saeki, Tetsu Tomonari, et al.
Oncology Letters (2024) Vol. 28, Iss. 2
Open Access | Times Cited: 7
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
George Lau, Shuntaro Obi, Jian Zhou, et al.
Hepatology International (2024) Vol. 18, Iss. 6, pp. 1661-1683
Open Access | Times Cited: 7
Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma
Ryoichi Miura, Atsushi Ono, Shigeki Yano, et al.
Medicine (2024) Vol. 103, Iss. 34, pp. e39289-e39289
Open Access | Times Cited: 5
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy
Issei Saeki, Shigeo Shimose, Tetsu Tomonari, et al.
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0311084-e0311084
Open Access | Times Cited: 5
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
Maria Cerreto, Ferdinando Cardone, Lucia Cerrito, et al.
Current Oncology (2023) Vol. 30, Iss. 10, pp. 8774-8792
Open Access | Times Cited: 12
Epidemiology of liver diseases: global disease burden and forecasted research trends
Jia Xiao, Fei Wang, Yuan Yuan, et al.
Science China Life Sciences (2024)
Closed Access | Times Cited: 4
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy
Bernhard Scheiner, Beodeul KANG, Lorenz Balcar, et al.
Hepatology (2024)
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top